Thyroid Ultrasonography: Much Ado About Nothing? A Provocative Analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: subcentimetric ITNs should not undergo thyroid US
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Addressing this overutilization requires a better understanding of contributing factors and targeted interventions. By restricting US to appropriate clinical scenarios, healthcare resources can be optimized without compromising patient outcomes, ensuring that rare cases of clinically significant thyroid cancer receive proper diagnosis and treatment.
Thyroid ultrasonography (US) usage has risen significantly over the past two decades, with annual increases of up to 21% in some healthcare systems.
APA
Petranović Ovčariček P, Giovanella L (2025). Thyroid Ultrasonography: Much Ado About Nothing? A Provocative Analysis.. Cancers, 17(11). https://doi.org/10.3390/cancers17111764
MLA
Petranović Ovčariček P, et al.. "Thyroid Ultrasonography: Much Ado About Nothing? A Provocative Analysis.." Cancers, vol. 17, no. 11, 2025.
PMID
40507245 ↗
Abstract 한글 요약
Thyroid ultrasonography (US) usage has risen significantly over the past two decades, with annual increases of up to 21% in some healthcare systems. This review examines patterns in thyroid US usage, factors driving potential misuse, and strategies to mitigate overuse. While thyroid US provides valuable information on thyroid morphology and structure without radiation exposure, inappropriate use-estimated at 10-50% of exams-leads to adverse consequences, including patient anxiety, unnecessary procedures, and potential overdiagnosis of thyroid cancer. The widespread adoption of US has coincided with increased thyroid cancer diagnoses, yet mortality rates remain unchanged, suggesting overdiagnosis rather than actual disease increase. Clinical guidelines consistently recommend selective US use not for routine evaluation of thyroid dysfunction (hyper/hypothyroidism) without palpable abnormalities, but for the anatomical assessment of palpable nodules. For thyroid incidentalomas (ITNs), evidence suggests negligible malignancy risk for nodules < 1 cm, arguing against further investigation. The paper proposes a rational approach to thyroid US, emphasizing that patients with thyroid dysfunction without palpable abnormalities, euthyroid patients without palpable nodules, and patients with subcentimetric ITNs should not undergo thyroid US. Addressing this overutilization requires a better understanding of contributing factors and targeted interventions. By restricting US to appropriate clinical scenarios, healthcare resources can be optimized without compromising patient outcomes, ensuring that rare cases of clinically significant thyroid cancer receive proper diagnosis and treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Marine-Lenhart syndrome: why nuclear medicine imaging remains essential for diagnosis and treatment.
- The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progress.
- Re: Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).
- Radioiodine-refractory thyroid cancer-is it time to change the definition in light of novel redifferentiation therapies?
- Clinical Advances in Thyroid Disease Assessment and Management.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening.
- Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
- Global economic differences in modern glioblastoma care - a systematic review.
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.
- Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
- Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.